Endothelin Receptor Inhibition with Bosentan Delays Onset of Liver Injury in Streptozotocin-Induced Diabetic Condition

Abstract

Background: This study was designed to investigate the protective effects of bosentan an orally active non-peptide mixed ETA/ETB receptor antagonist, on liver injury in streptozotocin-induced diabetic rats.

Methods: 24 Albino-Wistar rats were randomly divided into 4 groups: healthy (Group 1), diabetic (Group 2) (60 mg/kg of streptozotocin i.p.), diabetic treated with bosentan 50 mg/kg (Group 3) and diabetic treated with bosentan 100 mg/kg (Group 4). The treatment of bosentan was initiated after streptozocin injection and continued for 60 days.

Results: Liver from diabetic rats showed significant increase in malondialdehyde (MDA) level and significant decrease in glutathione (GSH), and superoxide dismutase (SOD) activity. Endothelin (ET-1), tumor necrosis factor (TNF-α) and transforming growth factor beta (TGF-β) gene expression significantly increased in the diabetic groups in the rat liver tissue. Bosentan treatment showed a significant up-regulatory effect on ET-1, TNF-α and TGF-β mRNA expression. Results from histopathological evaluation of the liver were in accordance with our biochemical and molecular results.

Conclusions: These data provide clear evidence that bosentan treatment is associated with promising hepatoprotective effect against diabetes-induced liver damage via reduction of cell inflammation and oxidative damage. These data suggest that ET receptors may be an important actor in diabetes-related liver damage, and blockage of these receptors may become a target for preventing diabetic complications in the future.

Key words

diabetes - liver - endothelin - cytokines - oxidative stress - rat

• References

• 1 Barakat GM, Moustafa ME, Bikhazi AB. Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats. Biochem Genet 2012; 50: 922-935
• 2 Hamadi N, Mansour A, Hassan MH et al. Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 2012; 26: 384-392
• 3 Gupta S, Kataria M, Gupta PK et al. Protective role of extracts of neem seeds in diabetes caused by streptozotocin in rats. J Ethnopharmacol 2004; 90: 185-189
• 4 Arkkila PE, Koskinen PJ, Kantola IM et al. Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes. Diabetes Res Clin Pract 2001; 52: 113-118
• 5 Saxena AK, Srivastava P, Kale RK et al. Impaired antioxidant status in diabetic rat liver. Effect of vanadate. Biochem Pharmacol 1993; 45: 539-542
• 6 Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76
• 7 Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454
• 8 Alexandraki KI, Piperi C, Ziakas PD et al. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol 2008; 28: 314-321
• 9 Deng D, Evans T, Mukherjee K et al. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-1234
• 10 Chakrabarti S, Cukiernik M, Hileeto D et al. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 2000; 16: 393-407
• 11 Sarman B, Somogyi A, Toth M. The role of endothelin-1 in diabetes mellitus. Orv Hetil 1998; 139: 217
• 12 Chen S, Evans T, Mukherjee K et al. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000; 32: 1621-1629
• 13 Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415
• 14 Estrada C, Gomez C, Martin C. Effects of TNF-alpha on the production of vasoactive substances by cerebral endothelial and smooth muscle cells in culture. J Cereb Blood Flow Metab 1995; 15: 920-928
• 15 Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 1996; 72: 261-290
• 16 Durieu-Trautmann O, Federici C, Creminon C et al. Nitric oxide and endothelin secretion by brain microvessel endothelial cells: regulation by cyclic nucleotides. J Cell Physiol 1993; 155: 104-111
• 17 Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587-590
• 18 Hu RM, Levin ER, Pedram A et al. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42: 351-358
• 19 Takeda Y, Miyamori I, Yoneda T et al. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci 1991; 48: 2553-2556
• 20 Roehrs M, Figueiredo CG, Zanchi MM et al. Bixin and norbixin have opposite effects on glycemia, lipidemia, and oxidative stress in streptozotocin-induced diabetic rats. Int J Endocrinol 2014; 2014: 839095
• 21 Schnedl WJ, Ferber S, Johnson JH et al. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 1994; 43: 1326-1333
• 22 Sakata N, Yoshimatsu G, Tsuchiya H et al. Animal models of diabetes mellitus for islet transplantation. Exp Diabetes Res 2012; 2012: 256707
• 23 de Souza LF, Barreto F, da Silva EG et al. Regulation of LPS stimulated ROS production in peritoneal macrophages from alloxan-induced diabetic rats: involvement of high glucose and PPARgamma. Life Sci 2007; 81: 153-159
• 24 Ghorbani A, Varedi M, Hadjzadeh MA et al. Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat. Exp Clin Endocrinol Diabetes 2010; 118: 442-448
• 25 Ghorbani A, Omrani GR, Hadjzadeh MA et al. Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme. Horm Metab Res 2013; 45: 221-225
• 26 Araz O, Demirci E, Yilmazel Ucar E et al. Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study. Multidiscip Respir Med 2013; 8: 74
• 27 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
• 28 Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
• 29 Gu D, Arnush M, Sarvetnick N. Endocrine/exocrine intermediate cells in streptozotocin-treated Ins-IFN-gamma transgenic mice. Pancreas 1997; 15: 246-250
• 30 Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract 2007; 13: 300-312
• 31 Harrison SA, Brunt EM, Goodman ZD et al. Diabetic hepatosclerosis: diabetic microangiopathy of the liver. Arch Pathol Lab Med 2006; 130: 27-32
• 32 Gandhi CR, Behal RH, Harvey SA et al. Hepatic effects of endothelin. Receptor characterization and endothelin-induced signal transduction in hepatocytes. Biochem J 1992; 287: 897-904
• 33 Degertekin B, Ozenirler S, Elbeg S et al. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007; 52: 2622-2628
• 34 Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev 1998; 14: 171-175
• 35 Hattori Y, Kasai K, Nakamura T et al. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism 1991; 40: 165-169
• 36 Gilbert RE, Rumble JR, Cao Z et al. Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res 2000; 86: 158-165
• 37 Katakam PV, Pollock JS, Pollock DM et al. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. Am J Physiol Heart Circ Physiol 2001; 280: H522-H527
• 38 Wu SQ, Hopfner RL, McNeill JR et al. Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 2000; 45: 994-1000
• 39 Sarafidis PA, Lasaridis AN. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?. J Cardiometab Syndr 2008; 3: 183-187
• 40 Sarafidis PA, Bakris GL. Review: Insulin and endothelin: an interplay contributing to hypertension development?. J Clin Endocrinol Metab 2007; 92: 379-385
• 41 Strawbridge AB, Elmendorf JS, Mather KJ. Interactions of endothelin and insulin: expanding parameters of insulin resistance. Curr Diabetes Rev 2006; 2: 317-327
• 42 Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072
• 43 Foss NT, Foss-Freitas MC, Ferreira MA et al. Impaired cytokine production by peripheral blood mononuclear cells in type 1 diabetic patients. Diabetes Metab 2007; 33: 439-443
• 44 Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996; 98: 1381-1388
• 45 Rockey DC, Housset CN, Friedman SL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993; 92: 1795-1804
• 46 Shao R, Yan W, Rockey DC. Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing. J Biol Chem 1999; 274: 3228-3234
• 47 Benz K, Amann K. Endothelin in diabetic renal disease. Contrib Nephrol 2011; 172: 139-148
• 48 Yayla M, Halici Z, Unal B et al. Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats. Eur J Pharmacol 2014; 726C: 87-95
• 49 Kurihara H, Yoshizumi M, Sugiyama T et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989; 159: 1435-1440
• 50 Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415
• 51 Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358
• 52 Rodriguez-Pascual F, Redondo-Horcajo M, Lamas S. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res 2003; 92: 1288-1295
• 53 Rodriguez-Pascual F, Reimunde FM, Redondo-Horcajo M et al. Transforming growth factor-beta induces endothelin-1 expression through activation of the Smad signaling pathway. J Cardiovasc Pharmacol 2004; 44 (Suppl. 01) S39-S42
• 54 Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005; 37: 2-12
• 55 Shi-wen X, Kennedy L, Renzoni EA et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007; 56: 4189-4194
• 56 Lee SD, Lee DS, Chun YG et al. Transforming growth factor-beta1 induces endothelin-1 in a bovine pulmonary artery endothelial cell line and rat lungs via cAMP. Pulm Pharmacol Ther 2000; 13: 257-265
• 57 Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012; 5: 272-281
• 58 Orhan N, Berkkan A, Deliorman Orhan D et al. Effects of Juniperus oxycedrus ssp. oxycedrus on tissue lipid peroxidation, trace elements (Cu, Zn, Fe) and blood glucose levels in experimental diabetes. J Ethnopharmacol 2011; 133: 759-764
• 59 Keter LK, Mutiso PC. Ethnobotanical studies of medicinal plants used by Traditional Health Practitioners in the management of diabetes in Lower Eastern Province, Kenya. J Ethnopharmacol 2012; 139: 74-80
• 60 Atangwho IJ, Ebong PE, Eyong EU et al. Synergistic antidiabetic activity of Vernonia amygdalina and Azadirachta indica: biochemical effects and possible mechanism. J Ethnopharmacol 2012; 141: 878-887
• 61 Nain P, Saini V, Sharma S et al. Antidiabetic and antioxidant potential of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol 2012; 142: 65-71
• 62 Stephen Irudayaraj S, Sunil C, Duraipandiyan V et al. Antidiabetic and antioxidant activities of Toddalia asiatica (L.) Lam. leaves in streptozotocin induced diabetic rats. J Ethnopharmacol 2012; 143: 515-523
• 63 Li L, Fink GD, Watts SW et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003; 107: 1053-1058
• 64 Callera GE, Touyz RM, Teixeira SA et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003; 42: 811-817
• 65 Elmarakby AA, Dabbs Loomis E, Pollock JS et al. ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats. J Cardiovasc Pharmacol 2004; 44 (Suppl. 01) S7-S10
• 66 Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004; 15 (Suppl. 01) S55-S57
• 67 Johnston CI, Risvanis J, Naitoh M et al. Mechanism of progression of renal disease: current hemodynamic concepts. J Hypertens Suppl 1998; 16: S3-S7
• 68 Touyz RM, Turgeon A, Schiffrin EL. Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2000; 36: S300-S304
• 69 Suga S, Yasui N, Yoshihara F et al. Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms. J Am Soc Nephrol 2003; 14: 397-406
• 70 Deng Y, He K, Ye X et al. Saponin rich fractions from Polygonatum odoratum (Mill.) Druce with more potential hypoglycemic effects. J Ethnopharmacol 2012; 141: 228-233
• 71 Orhan N, Aslan M, Pekcan M et al. Identification of hypoglycaemic compounds from berries of Juniperus oxycedrus subsp. oxycedrus through bioactivity guided isolation technique. J Ethnopharmacol 2012; 139: 110-118
• 72 Sasser JM, Sullivan JC, Hobbs JL et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18: 143-154
• 73 Thirunavukkarasu M, Penumathsa SV, Koneru S et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720-729